摘要
目的:探讨吡格列酮联合二甲双胍治疗非酒精性脂肪性肝病的疗效。方法:将非酒精性脂肪性肝病患者70例按随机双盲法分治疗组和对照组各35例,治疗组使用吡格列酮联合二甲双胍,比较两组疗效。结果:3个月时,两组的观察指标均有改善,虽治疗组更明显,但差异无统计学意义(P>0.05);6个月时,治疗组ALT、GGT、TG、HOMA-IR及疗效与对比组比较,差异有统计学意义(P<0.05)。结论:吡格列酮联合二甲双胍治疗NAFLD安全、有效,值得临床推广应用。
Objective： To discuss the safety and effectiveness of pioglitazone combined mefformin in the treatment of non-alcoholic fatty liver disease （ NAFLD ） . Method： 70 NAFLD patients were randomly divided into two groups, treatment group and control group, each group contained 35 cases, ALT, GGT, TG, HOMA-IR, BMI were compared between the two groups. Result： At the end of the 3rd month, the parameters were all improved but had no statistical difference （ P〉O.05 ） . At the end of the 6th month, ALT, TG, HOMA-IR and effectiveness of the treatment group was much better than that of the control group, the differences were significant （ P〈0.05 ） . Conclusion： Pioglitazone combined mefformin is safe and effective in the treatment of NAFLD.
出处
《中国医学创新》
CAS
2015年第25期69-72,共4页
Medical Innovation of China
基金
景德镇市科技计划项目(sf20141426)
